Clinical Trials

37 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05408845 2026-04-03

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Gynecologic

Endometrial Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04893109 2026-02-24

ATEMPT 2.0: Adjuvant T-DM1 vs TH

500 enrolled

Breast Neoplasms

NCT06595563 2026-02-19

ZEPHIR-02

87 enrolled

HER2-positive Metastatic Breast Cancer

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT05673928 2026-01-21

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

30 enrolled

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT07008976 2025-08-14

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

246 enrolled

Breast Neoplasms

NCT04341181 2025-07-25

ProTarget

300 enrolled

Tumor-Agnostic

Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT06126640 2025-05-02

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

1,600 enrolled

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

NCT05288777 2025-04-18

Breast53

Phase 2/3 Recruiting

45 enrolled

Breast Neoplasms

NCT04680442 2025-04-06

SCHOLAR-2

130 enrolled

Breast Neoplasms, Heart Failure

NCT06846437 2025-03-24

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

228 enrolled

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

NCT06313086 2024-05-10

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

442 enrolled

HER2-positive Breast Cancer

NCT06125834 2024-04-16

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

36 enrolled